Pathogenesis of Cardiac Allograft Vasculopathy (Chronic Rejection)

  • B. Arkonac
  • J. D. Hosenpud


Despite the dramatic improvement of early and 1-year survival following cardiac transplantation, long-term mortality has not been substantially impacted[1]. The major cause of late mortality is an accelerated obliterative coronary artery disease, presumably a manifestation of chronic rejection[2], which will be referred to in this review as cardiac allograft vasculopathy (CAV). The incidence of CAV is between 10% and 15% per year, with a prevalence of as high as 45% at 5 years based on angiographic diagnosis[3]. With the more sensitive intravascular ultrasound, some investigators have reported virtually 100% prevelance of the disease[4]. This review will focus on the pathophysiology and im munologic mechanisms proposed for CAV, as well as current diagnostic and potential therapeutic interventions for the disease.


Cardiac Transplantation Chronic Rejection Cardiac Allograft Heart Transplant Recipient Intimal Thickening 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hosenpud JD, Novick RJ, Breen TJ, Daily PO. The registry of the international society of heart and lung transplantation: eleventh official report-1994. J Heart Lung Transplant. 1994;13:561.PubMedGoogle Scholar
  2. 2.
    Hosenpud JD, Wagner CR, Shipley GD. Cardiac allograft vasculopathy: current concepts, recent developments and future directions. J Heart Lung Transplant. 1992; 11:9.PubMedGoogle Scholar
  3. 3.
    Gao SZ, Schroeder JS, Alderman EL et al. Prevalence of accelerated coronary artery disease in heart transplant survivors: comparison of cyclosporin and azathioprine regimens. Circulation. 1989;80(Suppl.):III–100.Google Scholar
  4. 4.
    St Goar FG, Pinto FJ, Alderman EL et al. Intracoronary ultrasound in cardiac transplant recipients: in-vivo evidence of angiographically silent intimal thickening. Circulation. 1992;85:979.PubMedGoogle Scholar
  5. 5.
    Ross R. Factors influencing atherogenesis. In: Hurst JW, editor. The heart. New York: McGraw-Hill; 1986:801.Google Scholar
  6. 6.
    Billingham ME. Cardiac transplant atherosclerosis. Transplant Proc. 1987; 19(Suppl. 5): 19.PubMedGoogle Scholar
  7. 7.
    Louie HW, Pang M, Lewis W et al. Immunohistochemical analysis of accelerated graft atherosclerosis in cardiac transplantation. Curr. Surg. 1989;46:479.PubMedGoogle Scholar
  8. 8.
    Ballester M, Obrador D, Carrio I et al. Reversal of rejection-induced coronary vasculitis detected early after heart transplantation with increased immunosuppression. J Heart Transplant 1989;8:413.PubMedGoogle Scholar
  9. 9.
    Paavonen T, Mennander A, Lautenschlager I et al. Endotheliilitis and accelerated arteriosclerosis in human heart transplant coronaries. J Heart Lung Transplant. 1993;12:117.PubMedGoogle Scholar
  10. 10.
    Oni AA, Ray JA, Hosenpud JD. Coronary venous intimal thickening in explanted cardiac allografts. Evidence demonstrating that transplant coronary artery disease is a manifestation of a diffuse allograft vasculopathy. Transplantation. 1992;53:1247.PubMedGoogle Scholar
  11. 11.
    Liu G, Butany J. Morphology of graft arteriosclerosis in cardiac transplant recipients. Hum. Pathol. 1992;23:768.PubMedGoogle Scholar
  12. 12.
    Lin H, Wilson JE, Kendall TJ et al. Comparable proximal and distal severity of intimal thickening and size of epicardial coronary arteries in transplant arteriopathy of human cardiac allografts. J Heart Lung Transplant. 1994;13:824.PubMedGoogle Scholar
  13. 13.
    Keogh A, Valantine H, Hunt S et al. Predictors of proximal epicardial artery disease after heart transplantation. J Heart Lung Transplant. 1991;10:188 (abstract).Google Scholar
  14. 14.
    Miller LW. Transplant coronary artery disease. (Editorial) J Heart Lung Transplant. 1992;11:S1.PubMedGoogle Scholar
  15. 15.
    Bajaj S, Shah A, Crandall C, Ibrahim H, Veirovec G et al. Coronary collateral circulation in the transplanted heart. Circulation. 1993;88;263.Google Scholar
  16. 16.
    Vora KN, Hosenpud JD, Ray J et al. Angina pectoris in a cardiac allograft recipient. Clin Transplant. 1991;5:20.Google Scholar
  17. 17.
    Stark RP, Mc Ginn AL, Wilson RF. Chest pain in cardiac transplant recipients: evidence of sensory reinnervation after cardiac transplantation. N Engl J Med. 1991;324:179.Google Scholar
  18. 18.
    Tuzcu ME, Hobbs RE, Rincon G et al. Occult and frequent transmission of atherosclerotic coronary disease with cardiac transplantation, insights from intravascular ultrasound. Circulation. 1995;91:1706.PubMedGoogle Scholar
  19. 19.
    Smart FW, Ballantyne CM, Cocanougher B et al. Insensitivity of noninvasive tests to detect coronary artery vasculopathy after heart transplant. Am J Cardiol. 1991;67:243.PubMedGoogle Scholar
  20. 20.
    Dressier FA, Miller LW. Necropsy versus angiography: how accurate is angiography? J Heart Lung Transplant. 1992; 11:S56.Google Scholar
  21. 21.
    Everett JP, Hershberger RE, Ratkovec RM et al. The specificity of normal quantitative angiography in excluding cardiac allograft vasculopathy. J Heart Lung Transplant. 1994;13:142.PubMedGoogle Scholar
  22. 22.
    St Goar FG, Fausto JP, Alderman EL et al. Intracoronary ultrasound in cardiac transplant recipients. In vivo evidence of angiographically silent intimal thickening. Circulation. 1992;85:979.Google Scholar
  23. 23.
    Ventura HO. Coronary artery imaging with intravascular ultrasound in patients following cardiac transplantation. Transplantation. 1992;53:216.PubMedGoogle Scholar
  24. 24.
    Ventura HO, White CJ, Jain SP et al. Assessment of intracoronary morphology in cardiac transplant recipients by angioscopy and intravascular ultrasound. Am J Cardiol. 1993;72:805.PubMedGoogle Scholar
  25. 25.
    Anderson TJ, Meredith IT, Uehata A et al. Functional significance of intimal thickening as detected by intravascular ultrasound early and late after cardiac transplantation. Circulation. 1993;88:1093.PubMedGoogle Scholar
  26. 26.
    Heroux AL, Silverman P, Costanzo MR et al. Intracoronary ultrasound assessment of morphological and functional abnormalities associated with cardiac allograft vasculopathy. Circulation. 1994;89:272.PubMedGoogle Scholar
  27. 27.
    Cocanougher B, Ballantyne CM, Pollack MS et al. Degree of HLA mismatch as a predictor of death from allograft arteriopathy after heart transplantation. Transplant Proc. 1993;25:233.PubMedGoogle Scholar
  28. 28.
    Costanzo-Nordin MR. Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility. J Heart Lung Transplant. 1992:11:S90 (review).PubMedGoogle Scholar
  29. 29.
    Rabin BS, Griffith BP, Hardesty RL. Vascular endothelial cell HLA-DR antigen and myocyte necrosis in human allograft rejection. J Heart Transplant. 1985:4:293.PubMedGoogle Scholar
  30. 30.
    Hayry P, Von Willebrand E, Anderson LC. Expression of HLA-ABC and-DR locus antigens on human kidney endothelial tubular and glomerular cells. Scand J Immunol. 1980:11:303.PubMedGoogle Scholar
  31. 31.
    Hart DNJ, Fuggle SV, Williams KA et al. Localization of HLA-ABC and DR antigens in human kidney. Transplantation. 1981;31:428.PubMedGoogle Scholar
  32. 32.
    Wagner CR, Vetto RM, Burger DR. Expression of I-region associated antigen (Ia) and interleukin-l by subcultured human endothelial cells. Cell Immunol. 1985;93:91.PubMedGoogle Scholar
  33. 33.
    Collin T, Korman AJ, Wake CT et al. Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain genes in human endothelial cells and dermal fibroblasts. Proc Natl Acad Sci USA. 1984;81:4917.Google Scholar
  34. 34.
    Wagner CR, Vetto RM, Burger DR. The mechanism of antigen presentation by endothelial cells. Immunobiology. 1984;168:453.PubMedGoogle Scholar
  35. 35.
    Wagner CR, Vetto RM, Burger DR. Subcultured endothelial cells can function independently as fully competent antigen-presenting cells. Hum Immunol. 1985;13:33.PubMedGoogle Scholar
  36. 36.
    Hirschberg H. Presentation of viral antigens by vascular endothelial cells in vitro. Hum Immunol. 1981;2:235.PubMedGoogle Scholar
  37. 37.
    Nunez G, Ball EJ, Stasny P. Accessory cell function of human endothelial cells. I. A sub-population of Ia positive cells is required for antigen presentation. J Immunol. 1983;131:666.PubMedGoogle Scholar
  38. 38.
    Hirschberg H, Bergh OJ, Thorsby E. Antigen presenting properties of human vascular endothelial cells. J Exp Med. 1981;152(Suppl.):249S.Google Scholar
  39. 39.
    Moen T, Moen M, Thorsby E. HLA D region products are expressed in endothelial cells. Tissue Antigens. 1980;15:112.PubMedGoogle Scholar
  40. 40.
    Carlos T, Gordon D, Fishbein D et al. Vascular adhesion molecule-1 is induced on endothelium during acute rejection in human cardiac allografts. J Heart Lung Transplant. 1992;11:1103.PubMedGoogle Scholar
  41. 41.
    Briscoe DM, Schoen FJ, Rice GE et al. Induced expression of endothelial-leukocyte adhesion molecules in human cardiac allografts. Transplantation. 1991;51:537.PubMedGoogle Scholar
  42. 42.
    Salomon RN, Hughes CCW, Schoen FJ et al. Human coronary transplantation-associated arteriosclerosis: evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol. 1991;138:791.PubMedGoogle Scholar
  43. 43.
    Theobald VA, Lauer JD, Kaplan FA et al. Neutral allografts lack of allogeneic stimulation by cultured human cells expressing MHC class I and class II antigens. Transplantation. 1993;55:128.PubMedGoogle Scholar
  44. 44.
    Fabry Z, Waldschmidt MM, Van Dyk L et al. Activation of CD4+ lymphocytes by syngeneic brain microvascular smooth muscle cells. J Immunol. 1990;15:1099.Google Scholar
  45. 45.
    Stovin PGI, Sharples L, Hutter JA et al. Some prognostic factors for the development of transplant-related coronary artery disease in human cardiac allografts. J Heart Lung Transplant. 1991;10:38.PubMedGoogle Scholar
  46. 46.
    Zerbe T, Uretsky B, Kormos R et al. Graft atherosclerosis: effects of cellular rejection and human lymphocyte antigen. J Heart Lung Transplant. 1992;11:S104.PubMedGoogle Scholar
  47. 47.
    Laden AMK. The effects of treatment on the arterial lesions of rat and rabbit cardiac allografts. Transplantation. 1972;13:281.PubMedGoogle Scholar
  48. 48.
    Fellstrom B, Dimeny E, Larsson E et al. Rapidly proliferative arteriopathy in cyclosporin-induced permanently surviving rat cardiac allografts simulating chronic vascular rejection. Clin Exp Immunol. 1990;80:288.PubMedGoogle Scholar
  49. 49.
    Adams DH, Tilney NL, Collins JJ et al. Experimental graft arteriosclerosis. Transplantation. 1992;53:1115.PubMedGoogle Scholar
  50. 50.
    Cramer DV, Qian S, Harnaha J et al. Cardiac transplantation in the rat. I. The effect of histocompatibility differences on graft arteriosclerosis. Transplantation. 1989;47:414.PubMedGoogle Scholar
  51. 51.
    Cramer DV, Chapman FA, Wu G-D et al. Cardiac transplantation in the rat. II. Alteration of the severity of donor graft arteriosclerosis by modulation of the host immune response. Transplantation. 1990;50:554.PubMedGoogle Scholar
  52. 52.
    Cramer DV, Wu G-D, Chapman FA et al. Lymphocytic subsets and histopathologic changes associated with the development of heart transplant arteriosclerosis. J Heart Lung Transplant. 1992;11:458.PubMedGoogle Scholar
  53. 53.
    Michel J-B, Plissonnier D, Bruneval P. The effect of perindopril on the immune arterial wall remodeling in the rat model of arterial graft rejection. Am J Med. 1992;92:39S.PubMedGoogle Scholar
  54. 54.
    Mennander A, Tiisala S, Halttunen J et al. Chronic rejection in rat aortic allografts. An experimental model for transplant arteriosclerosis. Arterioscler Thromb. 1991;11:671.PubMedGoogle Scholar
  55. 55.
    Isik FF, McDonald TO, Ferguson M et al. Transplant arteriosclerosis in a rat aortic model. Am J Pathol. 1992;141:1139.PubMedGoogle Scholar
  56. 56.
    Shi C, Russel ME, Bianchi C, Newell JB, Haber E. Murine model of accelerated transplant arteriosclerosis. Circ. Res. 1994;75:199.PubMedGoogle Scholar
  57. 57.
    Uretsky BF, Murali S, Reddy PS et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporin and prednisone. Circulation. 1987;76:827.PubMedGoogle Scholar
  58. 58.
    Liu G, Butany J. Morphology of graft arteriosclerosis in cardiac transplant recipients. Hum Pathol. 1992;23:768.PubMedGoogle Scholar
  59. 59.
    Hruban RH, Beschorner WE, Baumgartner WA et al. Accelerated arteriosclerosis in heart transplant recipients: an immunopathology study of 22 transplanted hearts. Transplant Proc. 1991;23:1230.PubMedGoogle Scholar
  60. 60.
    Salomon RN, Hughes CCW, Schoen FJ et al. Human coronary transplantation-associated arteriosclerosis: evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol. 1991;138:791.PubMedGoogle Scholar
  61. 61.
    Hosenpud JD, Shipley GD, Mauck KA, Morris TE, Wagner CR. The temporal reduction in acute rejection following cardiac transplantation is not associated with a reduction in cell-mediated responses to donor-specific vascular endothelium. J Heart Lung Transplant. 1995 (In press).Google Scholar
  62. 62.
    Hosenpud JD, Everett JP, Wagner CR et al. Cardiac allograft vasculopathy: association with cell-mediated but not humoral allo-immunity to donor specific vascular endothelium. Circulation. 1995 (In press).Google Scholar
  63. 63.
    Iwasaki Y, Talmage D, Stazl TE. Humoral antibodies in patients after renal homotransplantation. Transplantation. 1967;5:191.Google Scholar
  64. 64.
    Halloran PF, Schlaut J, Solez K et al. The significance of anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I like antibody. Transplantation. 1992;53:550.PubMedGoogle Scholar
  65. 65.
    Hammond EH, Yowell RL, Nunoda S et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant. 1989;8:430.PubMedGoogle Scholar
  66. 66.
    Hammond EH, Yowell RL, Price GD et al. Vascular rejection and its relationship to allograft coronary artery disease. J Heart Lung Transplant. 1992;11:S111.PubMedGoogle Scholar
  67. 67.
    Lavee J, Kormos RL, Duquesnoy RJ et al. Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation. J Heart Lung Transplant. 1991;10:921.PubMedGoogle Scholar
  68. 68.
    Smith JD, Danskine AJ, Rose ML et al. Specificity of lymphocytotoxic antibodies formed after cardiac transplantation and correlation with rejection episodes. Transplantation. 1992;53:1358.PubMedGoogle Scholar
  69. 69.
    Mehra MR, Ventura HO. Smart FW et al. Clinical relevance of vascular endothelial cell antigens in the genesis of cardiac allograft vasculopathy: an intravascular ultrasound study. Presented at the 1995 Annual Meeting of the American Society of Transplant Physicians, Chicago, IL.Google Scholar
  70. 70.
    Crisp SJ, Dunn MJ, Rose ML, Barbir M, Yacoub MH. Antiendothelial antibodies after heart transplantation: the accelerating factor in transplant-associated coronary artery disease. J Heart Lung Transplant. 1994;13:81.PubMedGoogle Scholar
  71. 71.
    Rose ML, Dunn M, Wheeler C, Collins A, Yacoub M. Identification of antiendothelial antibodies associated with accelerated coronary artery disease following cardiac transplantation. J Heart Lung Transplant. 1995;14:S49 (abstract).Google Scholar
  72. 72.
    Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts; importance of humoral immunity. J Immunol. 1994;152:5135.PubMedGoogle Scholar
  73. 73.
    Hosenpud JD, Shipley GD, Morris TE et al. The modulation of human aortic endothelial cell ICAM-1 (CD-54) expression by serum containing high titers of anti-HLA antibodies. Transplantation. 1993;55:405.PubMedGoogle Scholar
  74. 74.
    Morris TE, Wagner CR, Shipley GD et al. Regulation of endothelial-derived interleukin-6 (IL-6) by allogeneic lymphocytes. J Heart Lung Transplant. 1993;12:S95.Google Scholar
  75. 75.
    Goustin AS, Leof EB, Shipley GD et al. Growth factors and cancer. Cancer Res. 1986;46:1015.PubMedGoogle Scholar
  76. 76.
    Shipley GD, Keeble WW, Hendrickson JE et al. Growth of normal human keratinocytes and fibroblasts in serum-free medium is stimulated by acidic and basic fibroblast growth factor. J Cell Physiol. 1988;138:511.Google Scholar
  77. 77.
    Hoshi H, Kan M, Chen JK et al. Comparative endocrinology-paracrinology-autocrinology of human adult large vessel endothelial and smooth muscle cells. In Vitro Cell Dev Biol. 1988;24:309.Google Scholar
  78. 78.
    Gay CG, Winkles JA. Interleukin 1 regulates heparin-binding growth factor 2 gene expression in vascular smooth muscle cells. Proc Natl Acad Sci USA. 1991;88:296.PubMedGoogle Scholar
  79. 79.
    Loppnow H, Libby P. Proliferating or interleukin 1-activaled human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest. 1990;85:731.PubMedGoogle Scholar
  80. 80.
    Libby P, Ordovas JM, Birinyi LK et al. Inducible interleukin 1 gene expression in human vascular smooth muscle cells. J Clin Invest. 1986;78:1432.PubMedGoogle Scholar
  81. 81.
    Libby P, Warner SJC, Salomon RN et al. Production of platelet-derived growth factor-like mitogen by smooth muscle cells from human atheroma. N Engl J Med. 1988;318:1493.PubMedGoogle Scholar
  82. 82.
    Libby P, Janicka MW, Dinarello CA. Interleukin-1 (IL-1) promotes production by human endothelial cells of activity that stimulates the growth of arterial smooth muscle cells. Fed Proc. 1985;44:737 (abstract).Google Scholar
  83. 83.
    Raines EW, Dower SK, Ross R. Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science. 1989;243:393.PubMedGoogle Scholar
  84. 84.
    Hajjar KA. Hajjar DP, Silverstein RL et al. Tumor necrosis factor-mediated release of platelet-derived growth factor from cultured endothelial cells. J Exp Med. 1987;166:235.PubMedGoogle Scholar
  85. 85.
    Clausell N, Molossi S, Sett S, Rabinovitch M. In vivo blockade of tumor necrosis factor-α in cholesterol-fed rabbits after cardiac transplant inhibits acute coronary artery neointimal formation. Circulation. 1994:89:2768.PubMedGoogle Scholar
  86. 86.
    Russell ME, Wallace AF, Hancock WW et al. Upregulation of cytokines associated with macrophage activation in the Lewis-to-F344 rat transplantation model of chronic rejection. Transplantation. 1995;59:572.PubMedGoogle Scholar
  87. 87.
    Calderon TM, Sherman J, Wilkerson H et al. Interleukin 6 modulates c-sis gene expression in cultured human endothelial cells. Cell Immunol. 1992;143:118.PubMedGoogle Scholar
  88. 88.
    Ikeda U, Ikeda M, Oohara T et al. Interleukin 6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. Am J Physiol. 1991;260:H1713.PubMedGoogle Scholar
  89. 89.
    Oho S, Rabinovitch M. Post-cardiac transplant arteriopathy in piglets is associated with fragmentation of elastin and increased activity of a serine elastase. Am J Pathol. 1994;45:202.Google Scholar
  90. 90.
    Molossi S, Clausell N, Rabinovitch M. Coronary artery endothelial interleukin-1 mediates enhanced fibronectin production related to post-cardiac transplant arteriopathy in piglets. Circulation. 1993;88:248.Google Scholar
  91. 91.
    Zhao XM, Frist WH, Yeoh TK, Miller GG. Modification of alternative messenger RNA splicing of libroblast growth factor receptors in human cardiac allografts during rejection. J Clin Invest. 1994;94:992.PubMedGoogle Scholar
  92. 92.
    Zhao XM, Yeoh TK, Frist WH, Porterfield DL. Miller GG. Induction of acidic fibroblast growth factor and full-length platelet-derived growth factor expression in human cardiac allografts. Circulation. 1994;90:677.PubMedGoogle Scholar
  93. 93.
    Wagner CR, Morris TE, Shipley GD, Hosenpud JD. Regulation of human aortic endothelial cell-derived mesenchymal growth factors by allogeneic lymphocytes in vitro: a potential mechanism for cardiac allograft vasculopathy. J Clin Invest. 1993;92:1269.PubMedGoogle Scholar
  94. 94.
    Hosenpud JD, Morris TE, Shipley GD, Mauck KA, Wagner CR. Cardiac allograft vasculopathy: preferential regulation of endothelial cell-derived mesenchymal growth factors in response to a donor-specific allogeneic response. Transplantation. 1996;61:939.PubMedGoogle Scholar
  95. 95.
    Olivari MT, Homans DC, Wilson RF, Kubo SH, Ring WS. Coronary artery disease in cardiac transplant patients receiving triple-drug immunosuppressive therapy. Circulation. 1989;80(Suppl. III):111.Google Scholar
  96. 96.
    Pahl E, Fricker FJ, Armitage J et al. Coronary arteriosclerosis in pediatric heart transplant survivors: limitation of long-term survival. J Pediatr. 1990;116:177.PubMedGoogle Scholar
  97. 97.
    Winters GL, Kendall TJ, Radio SJ et al. Posttransplant obesity and hyperlipidemia: major predictors of severity of coronary arteriopathy in failed human heart allografts. J Heart Lung Transplant. 1990;9:364.Google Scholar
  98. 98.
    Eich D, Thompson JA, Daijin K et al. Hypercholesterolemia in long term survivors of heart transplantation: an early marker of accelerated coronary artery disease. J Heart Lung Transplant. 1991;10:45.PubMedGoogle Scholar
  99. 99.
    Sharples LD, Caine N, Mullins P et al. Risk factor analysis for the major hazards following heart transplantation-rejection, infection, and coronary occlusive disease. Transplantation. 1991;52:244.PubMedGoogle Scholar
  100. 100.
    Uretsky BF, Murali S, Reddy PS et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporin and prednisone. Circulation. 1987;76:827.PubMedGoogle Scholar
  101. 101.
    Carrier M, Pelletier GB, Genest J et al. Cholesterol-lowering intervention and coronary artery disease after cardiac transplantation. Ann Thorac Surg. 1994;57:353.PubMedGoogle Scholar
  102. 102.
    Johnson MR. Transplant coronary disease: nonimmunologic risk factors. J Heart Lung Transplant. 1992;11:S124.PubMedGoogle Scholar
  103. 103.
    Bilodeau M, Fitchett DH, Guerraty A, Sniderman AD. Dyslipoproteinemias after heart-lung transplantation: potential relation to accelerated graft arteriosclerosis. J Heart Transplant. 1989;8:454.PubMedGoogle Scholar
  104. 104.
    Grady KL, Costanzo-Nordin MR, Herold LS et al. Obesity and hyperlipidemia after heart transplantation. J Heart Lung Transplant. 1991;11:449.Google Scholar
  105. 105.
    Stamler JS, Vaughan DE, Rudd MA et al. Frequency of hypercholesterolemia after cardiac transplantation. Am J Cardiol. 1988;62:1268.PubMedGoogle Scholar
  106. 106.
    Becker DM, Markakis M, Sension M et al. Prevalence of hyperlipidemia in heart transplant recipients. Transplantation. 1987;44:323.PubMedGoogle Scholar
  107. 107.
    Farmer JA, Ballantyne CM, Frazier OH et al. Lipoprotein(a) and apolipoprotein changes after cardiac transplantation. J Am Coll Cardiol. 1991;18:926.PubMedGoogle Scholar
  108. 108.
    Ballantyne CM, Radovancevic B, Farmer JA et al. Hyperlipidemia after heart transplantation: report of a six year experience with treatment recommendations. J Am Coll Cardiol. 19??;19:1315.Google Scholar
  109. 109.
    Keogh A, Simons L, Spratt P et al. Hyperlipidemia after heart transplantation. J Heart Transplant. 1988;7:171.PubMedGoogle Scholar
  110. 110.
    Ost L. Effects of cyclosporin on prednisolone metabolism. (Letter) Lancet. 1984;1:451.PubMedGoogle Scholar
  111. 111.
    Butman SM. Hyperlipidemia alter cardiac transplantation: be aware and possibly wary of drug therapy for lowering of serum lipids. Am Heart J. 1991;121:1585.PubMedGoogle Scholar
  112. 112.
    Kobashigawa JA, Gleeson MP, Stevenson LW et al. Pravastatin lowers cholesterol and may prevent severe cardiac transplant rejection: a randomized trial. J Heart Lung Transplant. 1994;13:S75 (abstract).Google Scholar
  113. 113.
    Munoz E, Lonquist JL, Radovancevic B et al. Long-term results in diabetic patients undergoing heart transplantation. J Heart Lung Transplant. 1992;11:943.PubMedGoogle Scholar
  114. 114.
    Fields BL, Hoffman RM, Berkoff HA. Assessment of the impact of recipient age and organ ischemic time on heart transplant mortality. Transplant Proc. 1988;20:1035.PubMedGoogle Scholar
  115. 115.
    Hammond EH, Yowell RL, Price GD, Menlove RL et al. Vascular rejection and its relationship to development of transplantation-associated coronary arteriosclerosis. Transplant Proc. 1989;21:3677.Google Scholar
  116. 116.
    Grattan MT, Moreno-Cabral CE, Starnes VA et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. J Am Med Assoc. 1989;261:3561.Google Scholar
  117. 117.
    Loebe M, Schuler S, Zais O et al. Role of cytomegalovirus infection in the development of coronary artery disease in the transplanted heart. J Heart Transplant 1990;9:707.PubMedGoogle Scholar
  118. 118.
    McDonald K, Rector TS, Braunlin EA et al. Association of coronary artery disease in cardiac transplant patients with cytomegalovirus infection. Am J Cardiol. 1989;64:359.PubMedGoogle Scholar
  119. 119.
    Balk A, Linden M, Meeter K et al. Is there a relation between transplant coronary artery disease and the occurrence of CMV infection? J Heart Lung Transplant. 1991:10:188 (abstract).Google Scholar
  120. 120.
    Koskinen PK, Nieminen MS, Krogerus LA et al. Cytomegalovirus infection and accelerated cardiac allograft vasculopathy in human cardiac allografts. J Heart Lung Transplant. 1993;12:724.PubMedGoogle Scholar
  121. 121.
    Everett JP, Hersberger RE, Norman DJ et al. Prolonged cytomegalovirus infection with viremia is associated with development of cardiac allograft vasculopathy. J Heart Lung Transplant. 1992; 11:S133.PubMedGoogle Scholar
  122. 122.
    Wu T-C, Hruban RH, Ambinder RF et al. Demonstration of cytomegalovirus nucleic acids in the coronary arteries of transplanted hearts. Am J Pathol. 1992;140:739.PubMedGoogle Scholar
  123. 123.
    Lemstrom K, Persoons M, Bruggeman C et al. Cytomegalovirus infection enhances allograft arteriosclerosis in the rat. Transplant Proc. 1993;25:1406.PubMedGoogle Scholar
  124. 124.
    Waldman WJ, Adams PW, Orosz CG et al. T lymphocyte activation by cytomegalovirus-infected, allogeneic cultured human endothelial cells. Transplantation. 1992;54:887.PubMedGoogle Scholar
  125. 125.
    Sedinak DD, Roberts WH, Stephens RE et al. Inability of cytomegalovirus infection of cultured endothelial cells to induce HLA class II antigen expression. Transplantation. 1990;49:458.Google Scholar
  126. 126.
    Van Dorp WT, Johns E, Bruggeman CA et al. Direct induction of MHC class I. but not class II expression on endothelial cells by cytomegalovirus. Transplantation. 1989;48:469.PubMedGoogle Scholar
  127. 127.
    Tuder RM, Weinberg A, Panajotopoulos N, Kalil J. Cytomegalovirus infection amplifies class I major histocompatibility complex expression on cultured human endothelial cells. J Heart Lung Transplant. 1994;13:129.PubMedGoogle Scholar
  128. 128.
    Tumilowicz JJ, Gawlik ME, Powell BB, Trentin JJ. Replication of cytomegalovirus in human arterial smooth muscle cells. J Virol. 1985;56:839.PubMedGoogle Scholar
  129. 129.
    Hosenpud JD, Chou S, Wagner CR. Cytomegalovirus-induced regulation of major histocompatibility complex class I antigen expression in human aortic smooth muscle cells. Transplantation. 1991;52:896.PubMedGoogle Scholar
  130. 130.
    Keogh AM, Valantine HA, Hunt SA et al. Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation. J Heart Lung Transplant. 1992;11:892.PubMedGoogle Scholar
  131. 131.
    Sharples LD, Mullims PA, Cary NRB et al. A method of analyzing the onset and progression of coronary occlusive disease after transplantation and its effect on patient survival. J Heart Lung Transplant. 1993;12:381.PubMedGoogle Scholar
  132. 132.
    Gao SZ, Hunt SA, Schroeder JS et al. Does the rapidity of development of transplant coronary artery disease portend a worse prognosis. J Heart Lung Transplant. 1994;13:1119.PubMedGoogle Scholar
  133. 133.
    Muskett A, Burton NA, Eichwald EJ et al. The effect of antiplatelet drugs on graft atherosclerosis in rat heterotopic cardiac allografts. Transplant Proc. 1987;19:74.PubMedGoogle Scholar
  134. 134.
    Jacobsson J, Cheng L, Lyke K et al. Effect of estradiol on accelerated atherosclerosis in rabbit heterotopic aortic allografts. J Heart Lung Transplant. 1992;11:1188.PubMedGoogle Scholar
  135. 135.
    Eich DM, Nestler JE, Johnson DE et al. Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation. 1993;87:261.PubMedGoogle Scholar
  136. 136.
    Foegh ML. Angiopeptin: a treatment for accelerated myointimal hyperplasia. J Heart Lung Transplant. 1992;11:S28.PubMedGoogle Scholar
  137. 137.
    Arai S. Teramoto S, Senoo Y. The impact of FK506 on graft coronary artery disease of rat cardiac allograft-a comparison with cyclosporin. J Heart Lung Transplant. 1992; 11:757.PubMedGoogle Scholar
  138. 138.
    Raisanen-Sokolowski A, Yilmaz S, Tufveson G, Hayry P. Partial inhibition of allograft arteriosclerosis (chronic rejection) by 15-deoxyspergualin. Transplantation. 1994;57:1772.PubMedGoogle Scholar
  139. 139.
    Yun KL, Michie SA, Fann JI et al. Effects of fish oil on graft arteriosclerosis and MHC class II antigen expression in rat heterotopic cardiac allografts. J Heart Lung Transplant. 1991;10:1004.PubMedGoogle Scholar
  140. 140.
    Atkinson JB, Wudel JH, Hoff SJ, Stewart JR, Frist WH. Amlodipine reduces graft coronary artery disease in rat heterotopic cardiac allografts. J Heart Lung Transplant. 1993;12:1036.PubMedGoogle Scholar
  141. 141.
    Schroeder JS, Gao SZ, Alderman EA et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart transplant recipients. N Engl J Med. 1993;328:164.PubMedGoogle Scholar
  142. 142.
    Addonizio LJ, Hsu DT, Douglas JF et al. Decreasing incidence of coronary disease in pediatric cardiac transplant recipients using increased immunosuppression. Circulation. 1993;88:224.Google Scholar
  143. 143.
    Valantine H, Hunt S, Gamberg P et al. Impact of cyclosporin dose on long-term outcome after heart transplantation. Transplant Proc. 1994;26:2710.PubMedGoogle Scholar
  144. 144.
    Halle AA, Wilson RF, Vetrovec GW, for the Cardiac Transplant Angioplasty Study Group. Multicenter evaluation of percutaneous transluminal coronary angioplasty in heart transplant recipients. J Heart Lung Transplant. 1992;11:S138.PubMedGoogle Scholar
  145. 145.
    Jain SP, Ventura HO, Ramee SR et al. Directional coronary atherectomy in heart transplant recipients. J Heart Lung Transplant. 1993;12:819.PubMedGoogle Scholar
  146. 146.
    Copeland JG, Butman SM, Sehti G. Successful coronary artery bypass grafting for high-risk left main coronary artery atherosclerosis after cardiac transplantation. Ann Thorac Surg. 1990;49:106.PubMedGoogle Scholar
  147. 147.
    Gao SZ, Schroeder JS, Hunt S, Stinson EB. Retransplantation for severe accelerated coronary artery disease in heart transplant recipients. Am J Cardiol. 1988;62:876.PubMedGoogle Scholar
  148. 148.
    Ensley RD, Hunt S, Taylor DO et al. Predictors of survival after repeat heart transplantation. J Heart Lung Transplant. 1992:11:S142.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • B. Arkonac
  • J. D. Hosenpud

There are no affiliations available

Personalised recommendations